Anti-Infectives · LP-038
Metronidazole Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-038Anti-Infectives
- Generic identity
- MetronidazoleTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-038
- Generic identity
- Metronidazole
- Presentation
- Tablet
- Catalogue strength
- 200 mg; 400 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: metronidazole.
- Dosage form: tablet.
- Proposed strengths: 200 mg, 400 mg and 500 mg.
- General catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Strength-to-pack/SKU mapping; do not assume all three strengths use the same controlled presentation.
- Tablet coating, score/divisibility, exact excipients and release characteristics.
- Approved indications, route-specific warnings/interactions and administration instructions for the intended jurisdiction.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | 200 mg is not established by the external comparator label and requires exact product evidence. |
| B | 400 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | Do not infer composition/coating from other metronidazole strengths. |
| C | 500 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | External official labels are comparator context only. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Metronidazole is an antimicrobial used against selected anaerobic bacteria and certain protozoal infections. The indication and route are specific: an oral product is not equivalent to a skin or vaginal preparation. Its role should be established through diagnosis and current treatment guidance. This ingredient-level education does not provide a regimen or establish any approved Luang Pharma claim for the proposed tablet or oral suspension.
Clinical context and therapeutic role
Clinical contexts include selected dental, abdominal, genital and parasitic infections, but treatment depends on the organism, disease severity and local recommendations. Some conditions require combination therapy or a non-drug intervention; an ingredient catalogue cannot determine that plan. The clinician reviews liver function, neurologic history, pregnancy considerations and interacting medicines. Persistent or recurrent symptoms need reassessment because they may reflect a different diagnosis, reinfection or antimicrobial resistance.
Selected safety context
Nausea and a metallic taste are common. Numbness, tingling, balance problems, seizures or other neurologic changes need prompt medical review. Severe skin reactions and liver injury are uncommon but important. Alcohol and some alcohol-containing preparations may cause an unpleasant reaction; follow the exact label and pharmacist’s advice. Interactions with warfarin, lithium and other medicines require review. Severe diarrhoea, jaundice or signs of allergy should not be ignored.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Metronidazole tablets — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 1 July 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| NHS: MetronidazoleArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-038.
Professional enquiries
Request product-specific evidence for LP-038.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.